Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented a... ( Design Concept of Other Product -...)

Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008

Date:10/6/2008

Design Concept of Other Product - Company's Bioabsorbable Stent - Also Slated for Presentation at Symposium

HONG KONG, Oct. 6 /PRNewswire/ -- Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2008, in Washington, D.C.

Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam will provide a Genous clinical program update in an oral presentation at 4:10 p.m. EDT on Oct. 13 in Ballroom C at the Washington Convention Center. His presentation will include interim follow-up data from e-HEALING, a monitored, multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients.

In addition, de Winter and his colleagues will provide one-year follow-up data in an electronic poster that will be available for download and viewing throughout the convention center. Titled "One-year Clinical Outcome of a Real World Experience in Patients Treated with a Genous EPC Capturing Stent," the poster will reflect the use of the Genous stent in 236 patients who were considered to be mainly high risk in the study conducted exclusively at the Academic Medical Center.

Also scheduled for presentation in an electronic poster are one-, six- and 12-month follow-up data from studies involving acute myocardial infarction (AMI) patients at National University Hospital (NUH) in Singapore. The poster titled "The Impact of Endothelial Progenitor Cell Capture Stent Implantation in Patients with Acute Myocardial Infarction: Intermediate to Long Term Clinical Follow-Up" summarizes the studies conducted by Huay-Cheem Tan, M.D., and collaborators.

An additional electronic poster that demonstrates the clinical efficacy and safety of Genous versus a sirolimus-eluting stent and a bare metal stent in patients with ST-segment elevation myocardial infarction (S
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease

Post Your Comments:

Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented a...( Design Concept of Other Product -...),Health